AHIP’s Opposition of “Medicare for All Act of 2019”
On April 30, 2019, AHIP submitted a statement for a hearing in the House Rules Committee that focused on the “Medicare for All Act of 2019.”
Supporting the Medicare Advantage Quality Payment Relief Act
AHIP explains their support of the Medicare Advantage Quality Payment Relief Act
CMS finalizes Medicare Advantage and Part D Payment Policies
CMS issued a final rule April 1 to update 2020 payment policies for Medicare Advantage and Part D prescription drug plans.
BCBS Reduces Opioid Use Among Members by 56 Percent
Opioid use among Blue Shield of California members with noncancer pain fell 56 percent since 2014, the health insurer said March 18.
One in Five Patients Asked Doctors for Lower-Cost Medication Last Year
In an effort to reduce prescription drug costs in the last year, nearly one in every five patients asked their physician for a lower-cost medication, according to a new report from the CDC.
Seniors Satisfied With Medicare Supplemental Plan
Almost half — 46 percent — of adults aren't familiar with "Medicare for All" proposals, according to a survey from NORC at the University of Chicago.
Most Consumers Would Prepay For Prescriptions For A Discount
Sixty-four percent of consumers reported that they would jump on an opportunity to prepay for medications to receive a discounted price, according to a survey from DrFirst, a provider of e-prescribing and patient medication management solutions.
Nearly Half of Adults Unfamiliar with ‘Medicare for All’
Almost half — 46 percent — of adults aren't familiar with "Medicare for All" proposals, according to a survey from NORC at the University of Chicago.
Why Drug Prices Keep Going UP
Price hikes on existing drugs and new medications coming to market are the primary contributors to rising prescription drug prices, a new study published in Health Affairs reveals.
Winners & Losers Amid CMS’ Prescription Drug Policy Changes
CMS issued a proposed rule Nov. 26 that would allow insurers to implement broader use of step therapies or drop coverage of certain protected classes of drugs if price increases outpace inflation. Below is a breakdown of the winners and losers under the proposed rule changes.